ABOUT US

Overview

Oxy-17 LLC is a theranostics company committed to preventing Stroke and treatment of hypoxic-ischemic injury through Oxy-17Fusion™, its patented nanoemulsion metabolic MRI medium

This Nano-Oxygen delivering emulsion Oxy-17Fusion would be most appropriate in today's Corona COVID-19 in effectively ventilating those at risk & compromised patients. The PFD emulsion is based on an FDA approved PFD product that was voluntarily withdrawn due to shelf life stability issues. THIS ISSUE HAS BEEN FULLY RESOLVED BY US. THIS EMULSION COULD BE PRODUCED IN VERY SHORT TIME AND WILL OFFER A LIFE SAVING ALTERNATIVE TO VENTILATING COVID-19 AFFECTED PATIENTS. There are several published papers on Liquid ventilation using PFD emulsion.

Oxy-17 LLC has access to the world’s largest production source of Oxy-17® Gas, an enriched form of naturally available oxygen, in compliance with the cGMP requirement for medical gases, and commercially available in the United States and European Union for more than 25 years. Oxy-17 LLC's lead preclinical candidate, Oxy-17® Fusion, is the first ready-to-use intravenous formulation of Oxy-17® Gas; which will be commercialized in the United States, and in the European Union and other world markets with Strategic partners such as Nukem Isotopes GmbH and others

Management Team

Our management team brings more than 150 years of combined expertise in developing and securing regulatory approvals, and commercializing medical and diagnostic products at leading Fortune 100 companies in the U.S. and across the globe.

Pradeep M. Gupte

Founder, Chairman & CEO

pgupte@oxy-17.com

Pradeep M. Gupte founded the company in 1999 and brings over 25 years of experience in the biomedical sector. Formerly, Pradeep served as Director of Biomedical engineering and Assistant Hospital Director at Westchester Medical Center in Valhalla, NY and held faculty appointments at New York Medical College as a Research Associate Professor in the department of Surgery and Anesthesiology.

Pradeep specializes in the development and commercialization of diversified biomedical products, and has established Rockland Technimed Ltd. as an entity, raising funds, assembling the management team, overseeing the clinical program from discovery to commercialization, and coordinating operations.

Pradeep has authored more than 60 publications, 12 patents, and served on the editorial review board of the Journal of Clinical Engineering and Quest’s Prosthetics & Orthotics newsletter. In addition, Pradeep was an active contributor to the medical device standards for the American National Standards Institute and a member of the Technical Advisory Group (TAG) for European standards. Formerly a consultant and voting member of the FDA’s Device Good Manufacturing Practice Advisory Committee, Pradeep holds a B.S. in engineering from Gujarat University in India and an M.S. in Biomedical Engineering from Farleigh Dickinson University. Pradeep completed his thesis in Patient Data Management in Critical Care Decision Making at the Columbia Presbyterian Medical Center of Columbia University.

Jim Spearman, MBA

Vice Chairman, Board of Directors & President

jspearman@oxy-17.com

Board member since 2016.President and Vice Chairman. Prior to joining Rockland Technimed Ltd., Jim spent 28 years in corporate companies in the industrial, chemical and healthcare imaging & service sectors, including more than10 years with GE Healthcare. He has core competence in growth, operations, general management and quality, having led 17 Kaizen events at GE Healthcare and led successful passage of six ISO13485 audits. He also brings expertise in executive leadership & development, corporate finance & compliance, intellectual property creation & protection (successfully prosecuted two U.S. patents) and legal.

Robert L DeLaPaz, MD

Medical Director, Board of Directors

rdelapaz@oxy-17.com

Dr. Robert DeLaPaz joined the Board of Directors in 2002 and is currently a Professor Emeritus of Radiology and Emeritus Director of Neuroradiology at Columbia University - New York Presbyterian Hospital. As the university’s radiology CIO, Robert also directed the department-wide PACS effort while remaining actively involved in magnetic resonance imaging research. Dr. DeLaPaz is widely known for his work in applications of advanced techniques and functional MRI to analyze brain disorders and brain rehabilitation. Prior to joining Columbia & NYPH in 1995 Dr. DeLaPaz did his postgraduate medical training and held professorships in the medical schools at the NIH, Harvard University, UC San Francisco, Stanford University, Cornell University and Memorial Sloan Kettering Cancer Center.

James A. Baldwin, ESQ

Corporate Counsel & VP Finance, Board of Directors

jbaldwin@oxy-17.com

James A. Baldwin assumed the role of corporate counsel in 2012. James was a partner at Fox Rothschild LLP, and previously held positions at Piliero Mazza PLLC and Patton Boggs LLP. James concentrates his experience on mergers and acquisitions, with an emphasis on leveraged buyouts, private equity and venture capital deals. He also has experience in project finance deals; joint ventures; and formation and regulatory compliance of investment funds, including specialty investment companies such as small business investment companies (SBICs).

James has an extensive securities experience focusing on private placements, public offerings and public company reporting under the Securities Exchange Act of 1934, and a U.S. Small Business Administration regulatory practice with a concentration on 8(a), Veteran-owned, MBE, WBE, DBE certification and regulatory issues. James handles cross-border transactions and international project finance transactions and counsels clients on the structure and terms of their relationship with private and government parties involved in project developments in foreign markets, including China, Africa, Europe, Latin America and other emerging markets. His projects have primarily targeted the energy, heavy manufacturing, technology, telecommunications, infrastructure projects and financial service industries.

James was a co-founder of the charitable organization, Friends United for Need (F.U.N.) and provides tutoring and counseling for at-risk teenagers. He serves as a member of the Human Rights Committee for My Own Place, Inc. in Washington, D.C., and is a past board member for the Rock Ethics Board at the Pennsylvania State University. James also taught "Venture Capital and Technology Transactions, and Anatomy of a Deal: Mergers & Acquisitions Transactions" at Georgetown University Law Center for three semesters. James holds a J.D. degree from Georgetown University Law Center and a B.S. degree (Presidential Scholarship, full academic, Honors Program) from Villanova University.

Scientific Advisory Board

Dr. John Pile Spellman, M.D., F.A.C.R.

Dr. John Pile-Spellman joined the Scientific Advisory Board in 2008. John is recognized as an international leader in interventional neuroradiology, specializing in the diagnosis, management and treatment of cerebral aneurysms, strokes, tumors, vascular malformations and the development of innovative image-based services. Formerly a vice-chair of research and director of interventional MRI at Columbia University Medical Center, John continues his research activities at Columbia University’s School of Engineering in the biomedical engineering department. In addition, he has been an attending radiologist and director of academic interventional neuroradiology at New York Presbyterian Hospital. John has been published in more than 150 peer review journals and served as a reviewer of numerous academic publications, including Stroke, The Journal of Cerebral Blood Flow, Radiology, and Lancet. John received his undergraduate degree from the University of South Dakota and his medical degree from Tufts University School of Medicine in Boston, MA. He completed some neurosurgical training at Tufts New England Medical Center and a residency in Diagnostic Radiology at Massachusetts General Hospital in Boston, MA. He then completed fellowships in Neuroradiology at Massachusetts General Hospital and in Interventional Neuroradiology at New York University Medical Center.

Michael Moseley, Ph.D.

Dr. Michael Moseley joined the Scientific Advisory Board in 2002 and is currently an associate professor of radiology at the Radiological Sciences Laboratory at Stanford University School of Medicine. Michael was the former president of the International Society of Magnetic Resonance in Medicine (ISMRM) and remains active in guiding MR societies. Michael serves on four editorial boards and has authored more than 200 publications including Stroke, Radiology, Neurology and Science. He was the recipient of the ISMRM Gold Medal for Research in 2000 and his primary research interests’ focus on developing MR methods to detect the earliest effects of experimental and clinical cerebral ischemia. Michael received his medical training at University of California, San Francisco and earned his Ph.D. in biophysical nuclear magnetic resonance from Uppsala University in Sweden.

Dr. Ravinder Reddy, Ph.D.

Dr. Ravinder Reddy joined the Scientific Advisory Board in 2005 and is currently a professor of radiology at the University of Pennsylvania and a director of the Center for Magnetic Resonance and Optical Imaging, a NIH-funded research center. Ravinder’s research interests include novel, multinuclear magnetic resonance imaging and spectroscopic techniques for early diagnosis and quantification of physiological and functional parameters in pathologies such as arthritis, stroke, cancer and Alzheimer’s disease. Ravinder is the recipient of the prestigious National Merit Scholarship of the Government of India and serves as a member and chairman of the graduate thesis committee for the department of biochemistry and molecular biophysics at the University of Pennsylvania. Ravinder is an active member in the International Society of Magnetic Resonance Imaging in Medicine and the Osteoarthritis Research Society International, and serves as a referee for the Journal of Magnetic Resonance and Magnetic Resonance in Medicine. Ravinder holds a B.Sc. in math, physics and chemistry from Osmania University in Hyderabad, India, a M.Sc. in chemistry from Kakatiya University in Warangal, India and a Ph.D. in chemistry from the Indian Institute of Technology in Kanpur, India.